NIRVANA: Nicotinamide Riboside in SARS-CoV-2 patients for renal protection

This study is a pilot, double-blind, placebo-controlled, multicenter, interventional clinical trial with oral nicotinamide riboside (NR) 500 mg (versus placebo) twice daily for a total of 10 days in hospitalized participants with COVID-19. Biospecimens will be collected in participants.